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Abstract
Introduction: Angiotensin-converting enzyme (ACE) 2, a homolog of ACE, converts angiotensin (Ang) II into Ang(1-7), 
and the vasoprotective effects of Ang(1-7) have been documented. We explored the hypothesis that serum 
autoantibodies to ACE2 predispose patients with connective tissue diseases to constrictive vasculopathy, pulmonary 
arterial hypertension (PAH), or persistent digital ischemia.
Methods: Serum was examined from 42 patients with systemic lupus erythematosus (SLE), scleroderma, or mixed 
connective tissue disease. Eighteen vasculopathy patients with PAH (five cases) and/or persistent digital ischemia (16 
cases) were compared with 24 patients without these vasculopathies (control patients) for serum reactivity to purified 
recombinant human ACE2, using an ELISA.
Results: The sera from 17 of the 18 (94%) vasculopathy patients had ELISA scores above the baseline level determined 
using control sera from 28 healthy subjects, and the mean ELISA score in the vasculopathy patients was significantly 
higher than that in the control patients (P < 0.0005). The relative activity of serum ACE2, which was defined using a 
reference serum, correlated inversely with the ELISA scores for serum anti-ACE2 antibodies in the 18 vasculopathy 
patients (R2 = 0.6872). The IgG fraction from vasculopathy patients, but not from healthy subjects, inhibited ACE2 
activities in vitro. Consistent with this, immunosuppressive therapy given to one SLE patient with digital necrosis 
markedly decreased the anti-ACE2 antibody titer and restored serum ACE2 activity.
Conclusions: Autoantibodies to ACE2 may be associated with constrictive vasculopathies.
Introduction
Angiotensin-converting enzyme (ACE) 2, a homolog of
ACE, is a carboxypeptidase that degrades angiotensin
(Ang) II to Ang(1-7) [1]. Ang(1-7) has vasodilating, anti-
proliferative, and antithrombotic properties that antago-
nize the action of Ang II and play vasoprotective roles [2-
4]. Recent studies have demonstrated the therapeutic
effects of ACE2 activation by a synthetic molecule [5] or
of  ACE2  gene transfer [6] in experimental pulmonary
hypertension models.
Pulmonary arterial hypertension (PAH), a vasculopathy
of unknown etiology, is a serious complication of connec-
tive tissue disease (CTD) [7]. One clinical study found
reduced metabolism of ACE synthetic substrate in the
pulmonary vascular bed of PAH-CTD patients, but not in
primary PAH patients [8]. Persistent digital ischemia,
which manifests as skin ulcers or necrotic lesions, is
another intractable vasculopathy of CTD, and is strongly
associated with Raynaud's phenomenon. A correlation
between Raynaud's phenomenon and elevated systolic
pulmonary arterial pressure has been reported in patients
with systemic lupus erythematosus (SLE) [9]. PAH or
persistent digital ischemia is less frequent than Raynaud's
phenomenon, and these three vascular abnormalities are
involved in CTD patients across different disease entities,
including SLE, systemic sclerosis (SSc), and mixed con-
nective tissue disease (MCTD).
Our preliminary examination suggested the presence of
novel autoantibodies to ACE2 in the sera of two patients:
a patient with SLE suffering from severe digital necrosis,
and a patient with SSc accompanied by lethal PAH. Fur-
thermore, the sera of the two patients lacked ACE2 activ-
ity. These findings prompted us to conduct the present
study in order to explore the hypothesis that serum
autoantibodies to ACE2 predispose patients with CTD to
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constrictive vasculopathies; that is, PAH and persistent
digital ischemia.
Materials and methods
Study design
As many patients as possible among those with CTD and
PAH or persistent digital ischemia (vasculopathy
patients) in our hospital at time of the study were
enrolled. Sera from these patients were studied in com-
parison with those from CTD patients without vasculop-
athy or from healthy subjects. The ethics committee of
our hospital approved this study, and written informed
consent was obtained from all patients and control sub-
jects.
Serum sampling
Fresh serum was obtained from all of the patients and
normal subjects for the present study. Each serum sample
was aliquoted to avoid repeated thawing and was stocked
at -20°C until assayed.
Diagnosis of connective tissue disease
Forty-two patients with SLE, SSc, or MCTD were stud-
ied. SLE was diagnosed according to the classification cri-
teria of the American College of Rheumatology [10].
Patients with SSc met the classification criteria for the
diffuse (n = 3) or limited (n = 6) form of SSc, as described
in the literature [11]. Patients with MCTD met the crite-
ria for MCTD from Kasukawa and colleagues [12] and
the original definition of MCTD by Sharp and colleagues
[13].
Diagnosis of pulmonary arterial hypertension
PAH had been diagnosed in five patients with SSc, based
on dyspnea on exertion, elevated plasma brain natriuretic
peptide levels >100 pg/ml, right ventricular outflow and
peak tricuspid regurgitant pressure gradient exceeding 30
mmHg on echocardiography, exclusion of pulmonary
thromboembolism by high-resolution computed tomog-
raphy or pulmonary scintigraphy, and no deteriorated
lung fibrosis that could cause pulmonary hypertension.
Diagnosis of persistent digital ischemia
Each of the 16 patients in this category had persistent
cyanotic lesions on the digits, present for more than 2
years at the time of the present study, and a history of or
existing digital ulcers or necrosis. The radial artery pulse
in each patient was normal, and atherosclerotic ischemia
was excluded clinically. Three of the 16 patients also had
PAH.
Control patients
Serum samples from 24 CTD patients who had neither
PAH nor persistent digital ischemia were collected ran-
domly (that is, independent of the activity of their CTD)
on the ward or in the outpatient clinic. These samples
served as disease controls.
Normal control subjects
Serum samples were obtained from 28 healthy volunteers
(23 females and five males) who were free from any active
or chronic diseases, including hypertension. Before
bleeding, each subject was confirmed to have normal
blood pressure in the arms. The mean age of the 28 sub-
jects was 32.0 ± 9.5 years.
Detection of anti-ACE2 antibodies in patient serum
We established an ELISA using purified recombinant
human ACE2. A plasmid DNA-encoding human ACE2
cDNA, which was kindly gifted from Dr Hyeryun Choe
(Harvard Medical School, Cambridge, MA, USA), was
introduced into 293 free-style cells, according to the
manufacturer's protocol (Invitrogen, Carlsbad, CA,
USA). Culture supernatant was harvested on day 2 after
transfection, dialyzed against 25 mM Tris-Cl (pH 8.5),
and applied onto a DEAE column. ACE2 was eluted with
250 mM NaCl, and was dialyzed against for further use.
About 12.5 μg/ml recombinant human ACE2 were first
coated overnight onto a 96-well plate with bicarbonate
buffer (pH 9.6) at 4°C. The wells were then treated with a
blocking buffer composed of 5% BSA in PBS and washed
with buffer composed of 20 mM Tris-HCl (pH 7.5), 150
mM NaCl, and 0.1% Tween 20. The sera of the patients
and normal healthy volunteers were added to the plate
and incubated for 1 hour at room temperature. Bound
ACE2 antibodies were detected using horseradish peroxi-
dase-conjugated anti-human IgG antibody. The optical
density at 450 nm was measured after a 30-minute incu-
bation with SureBlue TMB microwell peroxidase sub-
strate (Kirkegaard & Perry Laboratories Inc.,
Gaithersburg, MD, USA). All samples were analyzed in
triplicate, and the values were normalized with the posi-
tive control.
Measurement of serum ACE2 activity
Zinc-dependent ACE2 enzymatic activity was measured
according to the methods described previously [14,15].
Briefly, 20 μM (7-methoxycoumarin-4-yl) acetyl-APK-
(2,4-dinitrophenyl)-OH (amino acids depicted by single
letters) (AnaSpec Inc., Fremont, CA, USA) - a fluorogenic
substrate [14] - was incubated with 1 μl test serum. Fluo-
rescence was monitored using Safire2 (TECAN, Männ-
edorf, Switzerland) at the excitation and emission
wavelengths of 320 nm and 450 nm, respectively.
Preliminary experiments revealed that the relative fluo-
rescence unit (RFU) value was not increased when the
substrate was simply incubated without the enzyme (data
not shown). Among 20 healthy humans, two samples
showed significantly high autofluorescence - in these
cases, the RFU values decreased during the incubationTakahashi et al. Arthritis Research & Therapy 2010, 12:R85
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even with the substrate. We excluded these samples
because it was not possible to evaluate the ACE2 enzyme
activity.
The RFU values obtained by the APK substrate were
almost completely inhibited by an ACE2 inhibitor, DX600
(Phoenix Pharmaceuticals Inc., Burlingame, CA, USA)
(Additional file 1). Additionally, the RFU values were sta-
tistically significant at both 60 and 70 minutes of the
incubation (Additional file 2). Based on these observa-
tions, we used the RFU values at 70 minutes without sub-
tracting the residual RFU counts resistant to DX600 [15].
The relative ACE2 activity (%) in each sample was further
calculated based on the level of ACE2 activity in a mix-
ture of serum samples from 28 healthy subjects (a refer-
ence serum). The assay was performed in triplicate and
the mean values of three independent measurements of
the ACE2 ELISA and ACE2 activity assay were used for
the statistical analysis by Student's t test.
Detection of serum ACE2 protein
An anti-human ACE2 goat polyclonal antibody (R&D
Systems, Minneapolis, MN, USA) was used for immuno-
precipitation. Serum was first treated for 15 minutes with
100 mM MgCl2, 70 units DNase I (Takara Bio Inc., Shiga,
Japan) and 500 μg/ml Ribonuclease A (Sigma, St Louis,
MO, USA) at room temperature, and was then incubated
with anti-human ACE2 antibody at 4°C for 2 hours. After
incubation, the immune complexes were recovered using
Protein G Sepharose™ 4 Fast Flow (GE Healthcare, Amer-
sham, Buckinghamshire, UK) and subjected to SDS-
PAGE, followed by western blot analysis. To detect ACE2
proteins, an anti-human ACE2 mouse monoclonal anti-
body was used (R&D Systems).
Purification of IgG from serum
Five microliters of serum were incubated with Protein G
Sepharose™ 4 Fast Flow in 20 mM sodium phosphate buf-
fer (pH 7.0) for 2 hours at 4°C. The immune complexes
were then washed and the IgG-bound beads eluted with
0.1 M glycine-HCl (pH 2.7). The recovered IgG was
immediately neutralized with 1 M Tris-HCl (pH 8.0). IgG
was detected by SDS-PAGE followed by Coomassie Bril-
liant Blue staining. IgG fractions were prepared from
three vasculopathy patients and three healthy subjects.
T h e  e ff ect  o f  ea c h  I g G  o n  t h e  a ct i vi t y  o f  r ec o m b i n a n t
human ACE2 (standard rACE2; R&D Systems) was
examined as described.
Results
Disease status of patients at the time of the present study
The demographics of patients with CTD and PAH or per-
sistent digital ischemia (vasculopathy patients, n = 18)
and of the control CTD patients (n = 24) are presented in
Table 1. The control patients had neither manifestations
nor a history of these vasculopathies.
Table 1: Patient demographics
Parameter Vasculopathy patients Control patients
Number of patients 18 (17 females, 1 male) 24 (21 females, 3 males)
Age (years) 50.5 ± 14.3 46.8 ± 17.8
Disease entities SLE (4), SSc (6), MCTD (8) SLE (21), SSc (2), MCTD (1)
Constrictive vasculopathies PAH (5); all patients had SSca; persistent 
digital ischemia (16)
None
Data presented as n or mean ± standard deviation. PAH, pulmonary arterial hypertension; MCTD, mixed connective tissue disease; SLE, 
systemic lupus erythematosus; SSc, systemic sclerosis. aThree patients also had digital ulcers; of these, one patient had a history of 
scleroderma renal crisis.
Figure 1 Summarized results of ELISA for detecting serum anti-
angiotensin-converting enzyme 2 antibodies. The ELISA scores of 
the vasculopathy patients (n = 18) are significantly higher than those 
of patients without vasculopathy (n = 24) and those of healthy subjects 
(n = 28). Bars indicate the median. P < 0.01.
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Vasculopathy patients
Of the 18 vasculopathy patients, three (Patients 1, 5, and
12) were hospitalized for treatment of an exacerbation of
their CTD. Patient 1, with SLE, had fever, pancytopenia,
and progressing digital necrosis of the fingers and toes.
Patient 5, with the diffuse form of SSc, was referred to our
hospital and admitted because of heart failure caused by
severe PAH of recent origin. Despite high-dose steroid
therapy for PAH and conventional therapy for heart fail-
ure, she died of sudden cardiac arrest. Patient 12, with
SLE, had fever, pancytopenia, diffuse erythema, and pain-
ful digital ischemia accompanied by chilblain lupus.
The remaining 15 outpatients (all had persistent digital
ischemia and four also had PAH) were being treated with
prostacyclins or calcium antagonists without apparent
improvement, and all of the patients with digital ischemia
had suffered from digital ulcers or digital necrosis within
2 years of the present study. In the five patients with PAH,
the mean ± standard deviation peak tricuspid regurgitant
pressure gradient was 51 ± 13 mmHg (range, 39 to 70
mmHg; median, 50 mmHg) on echocardiography within
6 months of the present study, and the mean plasma brain
natriuretic peptide level was 639 ± 623 pg/ml (range, 107
to 1,312 pg/ml; median, 568 pg/ml) at the time of this
study. Systemic hypertension was observed in four SLE
patients and in one SSc patient. Three of the patients had
been treated with a calcium antagonist or ACE inhibitor
for years, and hypertension developed in the remaining
two patients (Patients 1 and 12) during steroid therapy at
the time of study.
Control connective tissue disease patients
Of these 24 patients, 11 were hospitalized: nine patients
for exacerbated SLE (six with lupus nephritis, two with
neuropsychiatric lupus, and one with thrombocytope-
nia), one SLE patient for aseptic bone necrosis, and one
SSc patient for accidental cholecystitis. The remaining 13
outpatients had stable disease on a maintenance dose of
steroid therapy. Recent Raynaud's phenomena were
observed in two SLE patients, two SSc patients, and one
MCTD patient. Systemic hypertension was observed in
one SLE patient, who had been treated with an Ang II
receptor blocker.
ELISA for serum anti-ACE2 antibodies
All of the patients had received a maintenance dose of
steroid therapy by the time of blood sampling. Serum
samples were obtained from inpatients just before start-
ing additional immunosuppressive therapy for a disease
flare-up, and from outpatients. Sera from 17 of the 18
(94%) vasculopathy patients showed reactivity to ACE2
with ELISA values above the baseline level value, which
was determined as the mean ELISA score in the 28 nor-
Figure 2 Inhibition of angiotensin-converting enzyme 2 activity by IgG purified from patient serum. (a) Purified IgG from the sera of healthy 
volunteers (H1 to H3) and patients with vasculopathy (P1, P5, and P6) was detected by SDS-PAGE and Coomassie Brilliant Blue staining. The molecular 
weights of the heavy (50 kDa) and light (25 kDa) chains of IgG are shown. (b) The inhibition of angiotensin-converting enzyme (ACE) 2 activity by 5 
μg purified IgG was examined in triplicate assays. As a control, ACE2 activity in standard rACE2 was measured in the absence of IgG. As shown, ACE2 
activity was significantly reduced when the recombinant enzyme was co-incubated with IgG from the patients. P < 0.01. RFU, relative fluorescence 
unit.
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mal control subjects. The mean ELISA score was signifi-
cantly higher in the vasculopathy patients than in the
control patients (Figure 1). These results suggest that
anti-ACE2 antibodies in the serum are associated with
constrictive vasculopathies, PAH, or persistent digital
ischemia.
Inhibition of ACE2 activity by IgG purified from patient 
serum
IgG fractions from the sera of three healthy subjects and
three vasculopathy patients (Patients 1, 5, and 6) were
prepared (Figure 2a). The activity of standard rACE2 was
measured in 5 μg aliquots. The IgG fractions from the
vasculopathy patients, but not from the healthy subjects,
suppressed the rACE2 enzyme activity significantly com-
pared with that in the absence of IgG (Figure 2b).
Serum ACE2 activity in vasculopathy patients, control 
patients, and healthy subjects
First, the RFU value of the ACE2 enzyme activity, which
was blocked by DX600 (Additional file 1), was deter-
mined in 18 patients with vasculopathy, in 16 control
patients without vasculopathy, and in 26 healthy subjects.
The relative rate of serum ACE2 enzyme activity was
then compared with a reference mixture composed of
sera from healthy subjects. Serum ACE2 activity could
not be measured in one control patient and two healthy
subjects due to high fluorescence at the start of incuba-
tion, and sera from the remaining seven control patients
were not available for these experiments. The mean ±
standard deviation relative ACE2 activity was signifi-
cantly lower in the vasculopathy patients (64.8 ± 16.4, n =
18) compared with that in the healthy subjects (86.6 ±
32.2, n = 26, P = 0.0055) and control patients (165.1 ±
99.1, n = 16, P = 0.0010).
To clarify the correlation between ACE2 activity and
the presence of autoantibodies to ACE2, the ELISA
scores for serum anti-ACE2 antibodies and serum ACE2
activity were plotted (Figure 3). Our data indicate that the
titers of anti-ACE2 antibodies were inversely propor-
t i o n a l  t o  A C E 2  p e p t i d a s e  a c t i v i t y  i n  t h e  v a s c u l o p a t h y
patients (Figure 3c). In contrast, no correlation was
observed in the healthy subjects or control patients, sug-
gesting that the low serum ACE2 activities in most of the
vasculopathy patients were due to the presence of anti-
ACE2 antibodies. To assess ACE2 expression in the vas-
culopathy patients, we tested for ACE2 by immunopre-
cipitation followed by immunoblotting. As shown in
Figure 3d, the ACE2 levels in Patients 1 and 5, who were
deficient in ACE2 activity (Figure 3c), were comparable
with those in three healthy subjects, clearly indicating
that the decreased ACE2 activity in the vasculopathy
patients was due to a functional deficiency. The relative
ACE2 protein levels in the patients are shown in Addi-
Figure 3 Inverse correlation between the presence of angio-
tensin-converting enzyme 2 autoantibodies and activity in vas-
culopathy patients. The relative (%) activity of serum angiotensin-
converting enzyme (ACE) 2 compared with the reference value and 
ELISA score of the same sera were plotted in (a) 26 healthy subjects, (b) 
16 patients without vasculopathy, and (c) 18 vasculopathy patients, re-
spectively, and Pearson correlation coefficients were calculated. The 
relative ACE2 activities were determined based on a reference serum 
(mixed sera from healthy subjects). (d) Western blot analysis to detect 
ACE2 protein in serum. Immunoprecipitation followed by immunob-
lotting was performed on sera of healthy subjects (H1 to H3) and vas-
culopathy patients (P1 to P5). ACE2 was detected as a major band 
about 90 kDa in size (see also Additional file 3).
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tional file 3. The signal intensities of ACE2 protein and
the IgG heavy chain shown in Figure 3d were measured
and normalized.
Recovery of serum ACE2 activity after therapy in one 
patient
The exacerbated SLE and progressive necrosis of the fin-
gers and toes in Patient 1, a 25-year-old female, were
treated with intravenous methylprednisolone at a dose of
500 mg/day for 3 days, followed by 30 mg/day oral pred-
nisolone combined with three sessions of double-filtra-
tion plasmapheresis and conventional therapy, including
prostanoids, stellate ganglion anesthesia, and local care.
Her cutaneous lesions healed completely before dis-
charge, without amputation of any digits. Serum tests 2
months after the start of therapeutic intervention showed
that the ELISA score for anti-ACE2 antibodies was
reduced markedly (P < 0.05) (Figure 4a) and the ACE2
activity had recovered significantly (P < 0.05) (Figure 4b),
compared with the values before therapy. An ELISA for
anti-ACE2 antibodies in the waste double-filtration plas-
mapheresis fluid was negative, and thus we could not
evaluate whether double-filtration plasmapheresis had
removed these antibodies from the patient's blood. The
anti-ACE2 antibodies were probably decreased as a result
of immunosuppressive therapy using high-dose pulse ste-
roids.
The other two vasculopathy inpatients (Patients 5 and
12) also received immunosuppressive therapy during the
present study and had high ELISA scores for anti-ACE2
antibodies before therapy. The serum of Patient 5 was not
studied after therapy, because she died suddenly. For
Patient 12, the ELISA scores before therapy and after 2
months of therapy with 30 mg/day prednisolone were
0.68 ± 0.02 and 0.36 ± 0.01, respectively. These results
were not significantly different, and the titer tended to
decrease after therapy. The relative rates (%) of serum
ACE2 activity in this patient before and after therapy
were 52.2 ± 19.1 and 63.1 ± 4.8 (P = NS), based on the
level of activity detected in the reference sample, respec-
tively.
Discussion
Persistent digital ischemia and clinically evident PAH are
intractable and relatively infrequent complications of
SLE, SSc, and MCTD - although latent forms of vasculop-
athies, including sporadic abnormalities such as Ray-
naud's phenomena, may be more prevalent in CTD
patients. Immunosuppressive therapy can improve PAH
in some patients with SLE, SSc, or MCTD [16], and in
most SLE patients [17] via an unknown therapeutic
mechanism. The treatment of digital ischemia remains an
unsolved clinical problem for physicians. Our study sug-
gests, for the first time, that autoantibodies to ACE2 are
present in the serum of patients with persistent constric-
tive vasculopathies. Furthermore, the elevated ELISA
scores for anti-ACE2 antibodies correlated with reduced
ACE2 activity. The serum autoantibodies to ACE2 may
therefore inhibit ACE2 activity, and the inhibition may be
reversible after immunosuppressive therapy, based on the
data from Patient 1. There were small numbers of
patients with systemic hypertension in both the vasculop-
athy and control patient groups. We could not determine
Figure 4 Anti-angiotensin-converting enzyme 2 antibodies and activity in a systemic lupus erythematosus patient. Anti-angiotensin-con-
verting enzyme (ACE) 2 antibodies and ACE activity in a systemic lupus erythematosus patient (SLE) before and after therapy. (a) The ELISA score and 
(b) the ACE2 activity of Patient 1 (P1) recovered significantly after therapy.
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whether their hypertension was essential hypertension,
or was caused by steroid therapy or ACE2 inhibition.
The inhibition of ACE2 by autoantibodies may result in
reduced physiological levels of the vasoprotective agent
Ang(1-7) in the local vascular milieu, which may induce
vasculopathies in patients with underlying disease such as
CTD. Vasodilating drugs - including prostanoids,
endothelin-receptor antagonists, and phosphodiesterase
type-5 inhibitors - have been used widely to treat PAH
and have been partially effective for some PAH patients
[18]. No effective drugs have been found for persistent
digital ischemia [19]. Our study suggests that ACE2 acti-
vation or administration in experimental PAH [5,6] may
be applicable as a therapy for PAH or persistent digital
ischemia in patients with CTD.
Conclusions
Anti-ACE2 autoantibodies may be associated with con-
strictive vasculopathy in patients with connective tissue
disease.
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